Compare CCNE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | DRTS |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | Israel |
| Employees | 950 | 121 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.6M | 978.2M |
| IPO Year | N/A | N/A |
| Metric | CCNE | DRTS |
|---|---|---|
| Price | $35.05 | $11.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $34.50 | $8.67 |
| AVG Volume (30 Days) | 169.5K | ★ 784.7K |
| Earning Date | 04-20-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $7.00 | $699.98 |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.63 | $2.87 |
| 52 Week High | $34.92 | $14.11 |
| Indicator | CCNE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 52.93 |
| Support Level | $29.11 | $6.59 |
| Resistance Level | N/A | $14.11 |
| Average True Range (ATR) | 0.88 | 0.84 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 92.65 | 33.96 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.